Saab 9-5 to the base models and the Aero. Six-speed manual transmission was not offered in first-generation 9-5s. In 2005, an updated version of the 2.0 L turbocharged I4 was introduced in the European market together with the 2006 9-5. The engine was sold as "2.0T BioPower", optimized to run on E85 producing 132 kW (180 hp) at 5500 rpm. There was also a 2.3T BioPower version sold from 2007. It was also introduced in Australia. There is a Saab 9-5 E100 Concept, based on the turbo 2.0. The 9-5 introduced Saab's Active Head Restraints (SAHR), which moved up and forward to
7+3 (chemotherapy) anthracyclines. Addition of glucocorticoids (like prednisolone) or methotrexate or alkylating drugs (like cyclophosphamide or melphalan) to the "7+3" regimen is also of no benefit in AML. The addition of etoposide to the standard "7+3" regimen is "sometimes" of benefit in poor-risk patients (many of which are primary refractory to standard "7+3" induction regimens). It gave rise to the so-called ADE (or DAE = DA + etoposide) induction regimen in AML. The ADE induction (unlike, say, combinations of 7+3 with vinca alkaloids or prednisolone) is still sometimes used, especially in poor-risk AML patients. The addition of 6-thioguanine gave rise to the